TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06244459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR Assessment Tool
Description: Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
Study: NCT05839405

Intervention type: OTHER
Intervention: None - Cross Sectional.
Description: There is no intervention, this is cross-sectional only.

Intervention type: OTHER
Intervention: None - Cross Sectional.
Description: There is no intervention, this is cross-sectional only.

Intervention type: OTHER
Intervention: None - Cross Sectional.
Description: There is no intervention, this is cross-sectional only.
Study: NCT05402124

Intervention type: DRUG
Group type: OTHER
Intervention: acetylsalicylic acid delayed release tablets, 81mg
Description: acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
Study: NCT05795920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone injection in combination with gemcitabine
Description: Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
Study: NCT06227442

Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO criteria of 2010
Description: They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO criteria of 2010
Description: They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO criteria of 2010
Description: They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
Study: NCT06439628

Intervention type: DRUG
Intervention: Rimegepant
Description: patients take rimegepant to treat migraine attack as needed
Study: NCT06443801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY
Description: The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria.
Study: NCT06269016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expremental pre and post test
Description: effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expremental pre and post test
Description: effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
Study: NCT04782505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong
Study: NCT06162637

Intervention type: DEVICE
Group type: OTHER
Intervention: femoral neck locking plate
Description: femoral neck fractures fixation by femoral neck locking plate

Intervention type: DEVICE
Group type: OTHER
Intervention: multiple cannulated cancellous screws
Description: femoral neck fractures fixation by multiple cannulated cancellous screws
Study: NCT05065918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual violence and alcohol use harm reduction text message content
Description: The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alcohol use reduction content
Description: The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback).
Study: NCT06106789

Intervention type: DRUG
Intervention: Tobramycin inhalation solution
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.

Intervention type: DRUG
Intervention: Tobramycin inhalation solution
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.

Intervention type: DRUG
Intervention: Tobramycin inhalation solution
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.
Study: NCT06349317

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
Description: 1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle).
Study: NCT05983068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: solution for injection; by subcutaneous (SC) injection
Study: NCT05087667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Ortholoop cerclage
Description: implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Cerclage used in current practice
Description: implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
Study: NCT04978012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib and Camrelizumab
Description: Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
Study: NCT05571553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendations and reorientation towards healthcare resources
Description: Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care.
Study: NCT05217290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transtheoretical model
Description: The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
Study: NCT05146661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURESCUE device
Description: The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
Study: NCT06090019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine PICU nursing care for children on mechanical ventilator.
Description: Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-instructional module for VAP care bundle prevention
Description: Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
Study: NCT06247488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Description: Participant will receive oral dose of oxycodone 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Description: Participant will receive oral dose of oxycodone 20 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 20 mg
Description: Participant will receive oral dose of oxycodone 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 200 mg
Description: Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 200 mg
Description: Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 450 mg
Description: Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 450 mg
Description: Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
Study: NCT05212597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-valsartan
Description: 50mg\~100mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine-losartan
Description: amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
Study: NCT04774783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
Study: NCT06642363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s
Description: Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
Study: NCT06192017

Intervention type: DIAGNOSTIC_TEST
Intervention: WomEC
Description: The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
Study: NCT06111443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg [Farxiga]
Description: Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
Study: NCT06019962

Intervention type: DEVICE
Intervention: digital pelvic inclinometer
Description: It is a reliable and valid instrument for measuring pelvic tilt angle

Intervention type: DEVICE
Intervention: digital pelvic inclinometer
Description: It is a reliable and valid instrument for measuring pelvic tilt angle
Study: NCT05497336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: IBI351 is administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: IBI351 is administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is administered intravenously
Study: NCT06478602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
Study: NCT05236972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv drip Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
Study: NCT05220059

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT06250907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The guidance of dynamic navigation
Description: Osteotomy and implant placement with the guidance of dynamic navigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The guidance of static template
Description: Osteotomy and implant placement with the guidance of static template
Study: NCT05583279

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialetical Behavioral Therapy for Adolescents
Description: DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialetical Behavioral Therapy for Adolescents
Description: DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialetical Behavioral Therapy for Adolescents
Description: DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
Study: NCT05850897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masaj
Description: Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
Study: NCT05146063

Intervention type: DIAGNOSTIC_TEST
Intervention: Take the patient's subcutaneous fat tissue to detect the expression of LNK
Description: Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.

Intervention type: DIAGNOSTIC_TEST
Intervention: Take the patient's subcutaneous fat tissue to detect the expression of LNK
Description: Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
Study: NCT05137535

Intervention type: OTHER
Intervention: Questionnaire
Description: Family-based questionnaire
Study: NCT04875312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound cavitation in group A
Description: Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro acupuncture in group B
Description: Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)
Study: NCT05790187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of differents face pictures
Description: Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
Study: NCT06186726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: The patients received 72GyE/18 doses of carbon ion radiotherapy.
Study: NCT06460181

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: Manufactured by AstaReal Inc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manufactured by AstaReal Inc
Study: NCT06173804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Look Ahead Lifestyle Intervention
Description: Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
Study: NCT05215418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine/Topiramate Top Dose 15 mg/92 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Phentermine 30 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive oral capsule